Mindfulness meditation lowers muscle sympathetic nerve activity and blood pressure in African-American males with chronic kidney disease

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 307, Issue 1, 2014, Pages

  Park, Jeanie ^a,b   Lyles, Robert H ^c   Bauer Wu, Susan ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Chronic renal insufficiency; Mindfulness meditation; Muscle sympathetic nerve activity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BREATHING; BREATHING RATE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MEDITATION; MINDFULNESS; MINDFULNESS MEDITATION; MUSCLE SYMPATHETIC NERVE ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

CHRONIC RENAL INSUFFICIENCY; MINDFULNESS MEDITATION; MUSCLE SYMPATHETIC NERVE ACTIVITY;

AFRICAN AMERICANS; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; GEORGIA; HEART RATE; HUMANS; HYPERTENSION; MALE; MEDITATION; MIDDLE AGED; MINDFULNESS; MUSCLE, SKELETAL; RENAL INSUFFICIENCY, CHRONIC; RESPIRATORY RATE; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903602938     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00558.2013     Document Type: Article

References (57)

1. Abate NI, Mansour YH, Tuncel M, Arbique D, Chavoshan B, Kizilbash A, Howell-Stampley T, Vongpatanasin W, Victor RG. Overweight and sympathetic overactivity in black Americans. Hypertension 38: 379-383, 2001.
2. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11: 1469-1478, 2000.
3. Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, Tonkin A, Perkovic V. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 58: 1152-1161, 2011.
4. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. J Am Med Assoc 292: 2227-2236, 2004.
5. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 70: 1905-1913, 2006.
6. Barnes VA, Orme-Johnson DW. Prevention and treatment of cardiovascular disease in adolescents and adults through the transcendental meditation(R) program: A research review update. Current Hypertens Rev 8: 227-242, 2012.
7. Barnes VA, Pendergrast RA, Harshfield GA, Treiber FA. Impact of breathing awareness meditation on ambulatory blood pressure and sodium handling in prehypertensive African American adolescents. Ethn Dis 18: 1-5, 2008.
8. Bauer-Wu S. Mindfulness meditation. Oncology (Williston Park) 24: 36-40, 2010.
9. Bauer-Wu S, Sullivan AM, Rosenbaum E, Ott MJ, Powell M, McLoughlin M, Healey MW. Facing the challenges of hematopoietic stem cell transplantation with mindfulness meditation: a pilot study. Integrat Cancer Therap 7: 62-69, 2008.
10. Bedi US, Arora R. Cardiovascular manifestations of posttraumatic stress disorder. J Natl Med Assoc 99: 642-649, 2007.
11. Bernardi L, Porta C, Spicuzza L, Bellwon J, Spadacini G, Frey AW, Yeung LY, Sanderson JE, Pedretti R, Tramarin R. Slow breathing increases arterial baroreflex sensitivity in patients with chronic heart failure. Circulation 105: 143-145, 2002.
12. Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res 94: 37-45, 2004.
13. Blom K, Baker B, How M, Dai M, Irvine J, Abbey S, Abramson BL, Myers MG, Kiss A, Perkins NJ, Tobe SW. Hypertension analysis of stress reduction using mindfulness meditation and yoga: results from the Harmony Randomized Controlled Trial. Am J Hypertens 2013.
14. Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 6: 215-221, 2010.
15. Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun 21: 1038-1049, 2007.
16. Chapleau MW, Li Z, Meyrelles SS, Ma X, Abboud FM. Mechanisms determining sensitivity of baroreceptor afferents in health and disease. Annal NY Acad Sci 940: 1-19, 2001.
17. Chen Y, Yang X, Wang L, Zhang X. A randomized controlled trial of the effects of brief mindfulness meditation on anxiety symptoms and systolic blood pressure in Chinese nursing students. Nurse Education Today 33: 1166-1172, 2012.
18. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992.
19. Delius W, Hagbarth KE, Hongell A, Wallin BG. General characteristics of sympathetic activity in human muscle nerves. Acta Physiol Scand 84: 65-81, 1972.
20. Delius W, Hongell A, Hongell A, Wallin BG. Manoeuvres affecting sympathetic outflow in human muscle nerves. Acta Physiol Scand 84: 82-94, 1972.
21. Elias AN, Vaziri ND, Maksy M. Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis. Arch Intern Med 145: 1013-1015, 1985.
22. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
23. Goldstein CM, Josephson R, Xie S, Hughes JW. Current perspectives on the use of meditation to reduce blood pressure. Intl J Hypertens 2012: 578397, 2012.
24. Goso Y, Asanoi H, Ishise H, Kameyama T, Hirai T, Nozawa T, Takashima S, Umeno K, Inoue H. Respiratory modulation of muscle sympathetic nerve activity in patients with chronic heart failure. Circulation 104: 418-423, 2001.
25. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57: 846-851, 2011.
26. Guarnieri G, Grassi G, Barazzoni R, Zanetti M, Biolo G. The impact of inflammation on metabolic regulation in chronic kidney disease: a review. J Ren Nutr 15: 121-124, 2005.
27. Hughes JW, Fresco DM, Myerscough R, MHMvD, Carlson LE, Josephson R. Randomized controlled trial of mindfulness-based stress reduction for prehypertension. Psychosomatic Med 75: 721-728, 2013.
28. Ilies C, Bauer M, Berg P, Rosenberg J, Hedderich J, Bein B, Hinz J, Hanss R. Investigation of the agreement of a continuous non-invasive arterial pressure device in comparison with invasive radial artery measurement. Br J Anaesth 2011.
29. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21: 618-623, 1993.
30. Jeleazcov C, Krajinovic L, Munster T, Birkholz T, Fried R, Schuttler J, Fechner J. Precision and accuracy of a new device (CNAPTM) for continuous non-invasive arterial pressure monitoring: assessment during general anaesthesia. Br J Anaesth 105: 264-272, 2010.
31. Joseph CN, Porta C, Casucci G, Casiraghi N, Maffeis M, Rossi M, Bernardi L. Slow breathing improves arterial baroreflex sensitivity and decreases blood pressure in essential hypertension. Hypertension 46: 714-718, 2005.
32. Kingston J, Chadwick P, Meron D, Skinner TC. A pilot randomized control trial investigating the effect of mindfulness practice on pain tolerance, psychological well-being, and physiological activity. J Psychosomatic Res 62: 297-300, 2007.
33. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14: 3239-3244, 2003.
34. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006.
35. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 55: 270-276, 2010.
36. Malarkey WB, Jarjoura D, Klatt M. Workplace based mindfulness practice and inflammation: a randomized trial. Brain Behav Immun 27: 145-154, 2013.
37. Manikonda JP, Stork S, Togel S, Lobmuller A, Grunberg I, Bedel S, Schardt F, Angermann CE, Jahns R, Voelker W. Contemplative meditation reduces ambulatory blood pressure and stress-induced hypertension: a randomized pilot trial. J Hum Hypertens 22: 138-140, 2008.
38. Mano T, Iwase S, Toma S. Microneurography as a tool in clinical neurophysiology to investigate peripheral neural traffic in humans. Clin Neurophysiol 117: 2357-2384, 2006.
39. McClellan W, Warnock DG, McClure L, Campbell RC, Newsome BB, Howard V, Cushman M, Howard G. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 17: 1710-1715, 2006.
40. Nagae A, Fujita M, Kawarazaki H, Matsui H, Ando K, Fujita T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation 119: 978-986, 2009.
41. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 65: 1568-1576, 2004.
42. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 15: 2902-2907, 2004.
43. Nidich SI, Rainforth MV, Haaga DA, Hagelin J, Salerno JW, Travis F, Tanner M, Gaylord-King C, Grosswald S, Schneider RH. A randomized controlled trial on effects of the Transcendental Meditation program on blood pressure, psychological distress, and coping in young adults. Am J Hypertens 22: 1326-1331, 2009.
44. Oneda B, Ortega KC, Gusmao JL, Araujo TG, Mion D Jr. Sympathetic nerve activity is decreased during device-guided slow breathing. Hypertens Res 33: 708-712, 2010.
45. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 105: 1873-1876, 2008.
46. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Fiegel L, Hintze TH. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 84: 2091-2100, 1991.
47. Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, Rainforth M, Schneider R, Merz CN. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med 166: 1218-1224, 2006.
48. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R, Ferrari AU. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46: 1213-1218, 2005.
49. Rosenkranz MA, Davidson RJ, Maccoon DG, Sheridan JF, Kalin NH, Lutz A. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain Behavior Immun 27: 174-184, 2013.
50. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065, 2003.
51. Schneider RH, Alexander CN, Staggers F, Rainforth M, Salerno JW, Hartz A, Arndt S, Barnes VA, Nidich SI. Long-term effects of stress reduction on mortality in persons > or = 55 years of age with systemic hypertension. Am J Cardiol 95: 1060-1064, 2005.
52. Studinger P, Lenard Z, Mersich B, Reusz GS, Kollai M. Determinants of baroreflex function in juvenile end-stage renal disease. Kidney Int 69: 2236-2242, 2006.
53. System URD. USRDS 2010 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2012.
54. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 59: 919-957, 1979.
55. Wallin BG, Fagius J. Peripheral sympathetic neural activity in conscious humans. Annu Rev Physiol 50: 565-576, 1988.
56. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004.
57. Zeidan F, Johnson SK, Gordon NS, Goolkasian P. Effects of brief and sham mindfulness meditation on mood and cardiovascular variables. J Altern Complement Med 16: 867-873, 2010.